The Center for Biosimilars® recaps the top news for the week of December 31, 2018.
Transcript
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of December 31.
Number 5: A recent study evaluated the safety and efficacy of a single dose of rituximab for the treatment of idiopathic nephrotic syndrome in children.
Number 4: A new analysis shows that several key congressional leaders have received major contributions from the pharmaceutical industry.
Number 3: In comments submitted to CMS, the American College of Rheumatology expressed concern that the proposed International Pricing Index may disrupt patient access to care.
Number 2: JHL Biotech has announced that it randomized its first patient in a phase 3 study of JHL1101, a proposed biosimilar rituximab referencing Rituxan.
Number 1: A recent systematic review found that US and European providers are still taking a cautious approach to biosimilars, in part because of a lack of awareness of these medicines.
Finally, last week, our e-newsletter asked which area of biosimilar uptake is the most critical for payers to grapple with.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.